Home Crystal structure of 3-(2-(4-isobutylphenyl)propanoyl)-1-methylimidazolidine-2,4-dione, C17H22N2O3
Article Open Access

Crystal structure of 3-(2-(4-isobutylphenyl)propanoyl)-1-methylimidazolidine-2,4-dione, C17H22N2O3

  • Shi-Han Wang , Xiang-Qun Jin , Yan-Wei Wang and Yong-Sheng Wang EMAIL logo
Published/Copyright: May 8, 2017
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 232 Issue 4

Abstract

C17H22N2O3, monoclinic, P21/c, (no. 14) a = 18.419(4) Å, b = 5.7524(12) Å, c = 17.575(4) Å, β = 117.267(3)°, V =1655.2(6) Å3, Z = 4, Rgt(F) = 0.0724, wRref(F2) = 0.1899, T = 187(2) K.

CCDC no.:: 1480851

The asymmetric unit of the title crystal structure is shown in the figure. Hydrogen atoms are omitted for clarity. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colourless block
Size:0.21 × 0.18 × 0.11 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.8 cm−1
Diffractometer, scan mode:Bruker APEXII, φ and ω
2θmax, completeness:52.8°, >99%
N(hkl)measured, N(hkl)unique, Rint:8567, 3355, 0.045
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2137
N(param)refined:232
Programs:Bruker [1], SHELX [2]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C1a0.4599(9)−0.411(2)0.8904(6)0.097(4)
H1Aa0.4453−0.57480.87590.145*
H1Ba0.4342−0.35330.92470.145*
H1Ca0.5194−0.39690.92330.145*
C1’a0.4528(7)−0.295(2)0.9233(7)0.094(4)
H1’Aa0.4948−0.21850.97440.140*
H1’Ba0.4741−0.44210.91380.140*
H1’Ca0.4044−0.32460.93130.140*
C2a0.4309(5)−0.2720(19)0.8103(5)0.068(2)
H2Aa0.4351−0.38220.76850.082*
C2’a0.4286(6)−0.1289(18)0.8418(6)0.084(4)
H2’a0.4650−0.20240.82050.101*
C3b0.4957(3)−0.0918(14)0.8250(4)0.087(2)
H3Ab0.47790.00670.77400.130*
H3Bb0.5469−0.16980.83590.130*
H3Cb0.50430.00450.87440.130*
C3’c0.4618(9)0.065(3)0.8583(9)0.089(5)
H3’Ac0.43240.16940.80980.133*
H3’Bc0.51860.04930.86870.133*
H3’Cc0.46060.12820.90940.133*
C40.3503(2)−0.2073(7)0.77167(19)0.0569(9)
H4A0.3405−0.11730.81410.068*
H4B0.3173−0.35090.75960.068*
C50.31678(17)−0.0671(6)0.69016(17)0.0425(7)
C60.32311(19)−0.1494(5)0.61925(18)0.0455(8)
H6A0.3498−0.29340.62300.055*
C70.29163(18)−0.0269(5)0.54361(18)0.0437(7)
H7A0.2972−0.08760.49630.052*
C80.25185(16)0.1835(5)0.53525(16)0.0327(6)
C90.24489(17)0.2672(5)0.60447(17)0.0397(7)
H9A0.21750.41050.59990.048*
C100.27761(17)0.1446(6)0.68206(18)0.0442(8)
H10A0.27290.20700.72970.053*
C110.21897(17)0.3179(5)0.45082(17)0.0381(7)
H11A0.18620.45280.45390.046*
C120.2877(2)0.4097(6)0.4329(2)0.0541(9)
H12A0.26430.50510.38090.081*
H12B0.31740.27850.42490.081*
H12C0.32520.50420.48140.081*
C130.16354(18)0.1598(5)0.37835(17)0.0407(7)
C140.04497(19)−0.1123(5)0.33390(18)0.0451(8)
C15−0.03161(19)−0.1134(5)0.34351(19)0.0459(8)
H15A−0.0805−0.10560.28700.055*
H15B−0.0349−0.25470.37390.055*
C160.04303(16)0.2164(5)0.41027(16)0.0338(6)
C17−0.09250(18)0.1915(6)0.4026(2)0.0515(8)
H17A−0.07300.32120.44330.077*
H17B−0.11650.07210.42400.077*
H17C−0.13390.24790.34690.077*
N10.08919(14)0.0872(4)0.37723(13)0.0368(6)
N2−0.02442(14)0.0927(4)0.39325(14)0.0378(6)
O10.18075(14)0.0879(5)0.32445(13)0.0644(7)
O20.06259(12)0.4020(4)0.44656(13)0.0478(6)
O30.06621(16)−0.2551(4)0.29864(15)0.0669(7)

  1. aOccupancy: 0.5; bOccupancy: 0.7; cOccupancy: 0.3.

Source of material

Ibuprofen ((4-isobutylphenyl)propionic acid; 6.0 g, 29 mmol) and SOCl2 (3.5 g, 30 mmol) were added to 20 mL of CH2Cl2. After refluxing for 1.5 h, the reaction solution was added dropwise into another solution of 1-methylhydantoin (1-methylimidazolidine-2,4-dione; 3.3 g, 29 mmol) and pyridine (6.0 g, 60 mmol) at room temperature and stirred for 4 h. After reacting, the mixture was filtered and concentrated to give a crude product. The crude product was purified by recrystallization in ethyl acetate and n-hexane (v/v, 1:30). Colorless block-shaped crystals were obtained (yield: 85%). 1H-NMR (CDCl3, 400 MHz): 0.89 (d, J = 6.8 Hz, 6H, 2CH3), 1.49 (d, J = 6.8 Hz, 3H, CH3), 1.83–1.85 (m, 1H, CH), 2.42 (d, J = 7.2 Hz, 2H, CH2), 2.93 (s, 3H, CH3), 3.77 (s, 2H, CH2), 4.85 (q, J = 6.8 Hz, 1H, CH), 7.07 (d, J = 8.0 Hz, 2H, 2ArH), 7.16 (d, J = 8.0 Hz, 2H, 2ArH); 13C-NMR (CDCl3, 100 MHz): 172.58, 166.93, 152.86, 140.88, 136.68, 129.57, 129.57, 127.64, 127.64, 50.85, 46.62, 44.97, 30.06, 29.52, 22.32, 22.32, 18.57; ESI-MS [M + H]+, m/z: 303.3; Found: 303.1712.

Experimental details

All H atoms were placed in calculated positions and refined using the riding model approximation. For the methyl groups, C—H bonds were fixed at 0.98 Å, the Uiso values of the hydrogen atoms of methyl groups were set to 1.5 Ueq(C) and the Uiso values of all other hydrogen atoms were set to 1.2 Ueq (C), with aromatic C—H distances of 0.95 Å. The isopropyl moiety is disordered over two split positions (cf. the figure).

Discussion

Qviductus Ranne [3] has significant pharmacological activities, mainly in anti-oxidation, anti-inflammatory, anti-anxiety, antitussive, and anti-fatigue [4], [5], [6], [7]. 1-Methylhydantoin, as a main effective constituent in Oviducts Ranne, has been widely used in pharmaceutical industry [8]. The synthesis and structure characterization of 1-methylhydantoin derivatives are quite important in academia and medicinal applications [9]. A series of 1-methylhydantoin derivatives were successfully synthesized in our previous studies [10]. On the other hand, ibuprofen is a widely used anti-inflammatory drug. Therefore, the combination of 1-methylhydantoin and ibuprofen has emerged. The coupling reaction of 1-methylhydantoin with ibuprofen was carried out by nucleophilic substitution. 1-Methylhydantoin ibuprofen was purified through crystallization process and showed a lot of biological activities, such as anti-inflammatory, antitussive [10], analgesic and gastric ulcerogenic [11].

The asymmetric unit of the title crystal structure consists of one molecule. There are no hydrogen bonds between adjacent molecules. All bond lengths and angles are in the expected ranges. The imidazole ring and the phenyl ring are not on the same plane, the bond lengths of C13—N1, C14—N1 and C16—N1 are 1.423(4) Å, 1.437(3) Å and 1.411(4) Å, respectively. The angles of C14—N1—C13, C14—N1—C16 and C13—N1—C16 are 124.1(2)°, 109.7(2)°, 125.9(2)°, respectively.

Acknowledgement

The authors extend their appreciatetion to College of Pharmacy at Jilin University for their funding of this research.

References

1 Bruker. APEX2, SAINT and SADABS. Brucker AXS Inc., Madison, Wisconsin, USA, (2009).Search in Google Scholar

2 Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Search in Google Scholar PubMed PubMed Central

3 Wang, Y.; Zhang, H.; Lin, K.; Wang, Z.: Study on determination of 1-methylhydantoin in oviductusranae by RP-HPLC assay. Chin. Pharm. J. 43 (2008) 146–148.Search in Google Scholar

4 Fan, Y.; Cui, X.; Yao, Y.; Wei, Q.: Study on components in the oviduct of chinese forest frog. J. Jilin Agric. Uni. 18 (1996) 105–111.Search in Google Scholar

5 Ienaga, K.; Yokozawa, T.: Treatment with NZ-419(5-hydroxy-1-methylimidazoline-2,4-dione), a novel intrinsic antioxidant, against the progression of chronic kidney disease at stages 3 and 4 in rats. Biol. Pharm. Bull. 33 (2010) 809–815.10.1248/bpb.33.809Search in Google Scholar PubMed

6 Amaral-Machado, L.; Xavier-Jnior, F. H.; Rutckeviski, R.; Morais, A. R. V.; Alencar, É. N.; Dantas, T. R. F.; Cruz, A. K. M.; Genre, J.; da Silva-Junior, A. A.; Pedrosa, M. F. F.; Rocha, H. A. O.; Egito, E. S. T.: New trends on antineoplastic therapy research: Bullfrog (Rana catesbeiana Shaw) oil nanostructured systems. Molecules 21 (2016) 585.10.3390/molecules21050585Search in Google Scholar PubMed PubMed Central

7 Zhang, T. H.; Wu, Z.; Chen, Y.; Li, D.-C.; Zhang, T.; Ye, H.-Q.: Rana oil and ginseng saponin compound type oral liquid significantly enhanced immune function in mice. In: Medicine and Biopharmaceutical: Proceedings of the 2015 International Conference (Ed. M. Takahashi) p. 940–949. World Scientific 2016.10.1142/9789814719810_0121Search in Google Scholar

8 Delgado, G. E.; Mora, A. J.; Contreras. J. E.; Chacón; X-ray powder diffraction data for 1-methylhydantoin, an antiasthmatic and antidepressive hydantoin compound. Powder Diffr. 30 (2015) 178–181.10.1017/S0885715615000081Search in Google Scholar

9 Yang, B.; Liu, D.; Li, C. Z.; Liu, F. Y.; Peng, Y. M.; Jiang, Y. S.: 1-Methylhydantoin cytotoxicity on renal proximal tubular cells in vitro. Ren. Fail. 29 (2007) 1025–1029.10.1080/08860220701641272Search in Google Scholar PubMed

10 Lu, H.; Kong, D.; Wu, B.; Wang, S.; Wang, Y.: Synthesis and evaluation of anti-inflammatory and anti-tussive activity of hydantoin derivatives. Lett. Drug. Des. Discov. 9 (2012) 638–642.10.2174/157018012800673092Search in Google Scholar

11 Lu, H.; Xu, Y.; Wang, S.; Chen, B.; Qiao, L.; Wang, Y.; Yang, P.; Mao, C.: Synthesis, evaluation of analgesic and gastric ulcerogenic activities and the metabolites in rat plasma of hydantoin ibuprofen conjugates. Lett. Drug. Des. Discov. 10 (2013) 895–899.10.2174/15701808113109990005Search in Google Scholar

Received: 2016-12-4
Accepted: 2017-4-12
Published Online: 2017-5-8
Published in Print: 2017-7-26

©2017 Shi-Han Wang et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Crystal structure of poly[diaqua-(μ2-4,4′-bipyridine-κ2N:N′)manganese(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2) C42H40Cl2MnN6O10S2
  3. The crystal structure of 1,2-bis[2-methyl-5-(3-cyanophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluoro-cyclopent-1-ene, C29H16F6N2S2
  4. Crystal structure of the first characterized polymeric copper and sodium complex diaqua-(tris-acetato-κO,O′)(μ2-acetato-κO′′)dinatrium copper(II) monohydrate, C8H18CuNa2O11
  5. The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-3-yl-methylene)aniline, C18H22N2
  6. Crystal structure of methyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22N2O5
  7. Crystal structure of bis(1,3-bis(diphenylphosphino)propane-κ2P,P′)silver(I) trifluorosulfonate–methanol (1:0.5), [Ag(C27H26P2)]SO3CF3⋅0.5CH3OH
  8. Crystal structure of μ-1,4-bis(diphenylphosphine)butane-2,9-dimethyl-1,10-phenanthroline-κ2N:N′-bis(cyano-κC)dicopper(I)]-water, C58H56Cu2N6O2P2
  9. Crystal structure of N2,N6-bis(1-hydrazinyl-2-methyl-1-oxopropan-2-yl) pyridine-2,6-dicarboxamide, C15H23N7O4
  10. Crystal structure of 1,3-dimethyl-2-phenyl-1H-perimidin-3-ium iodide, C19H17IN2
  11. Crystal structure of diaqua-(2,2′-(butane-1,4-diyl)-bis(5-carboxy-1H-imidazole-4-carboxylato)-κ4O,O′,N,N′)cadmium(II) monohydrate, C14H18O11N4Cd
  12. Crystal structure of ethyl (E)-3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate, C15H14Cl2FNO3
  13. Crystal structure of bis-(1-(4-chlorophenyl)-3-phenyl-4-thenoyl-1H-pyrazol-5-ol-κ2O,O′)-(N,N-dimethylformamide)zinc(II), C43H31Cl2N5O5S2Zn
  14. Crystal structure of tetrakis(μ3-2-(N-(2-hydroxyethyl)amino)ethoxo)-tetrachloro-tetra-cobalt(II) methanol solvate, C17H44Cl4Co4N4O9
  15. Crystal structure of 3-amino-1-(4-bromophenyl)-9-methoxy-1H-benzo[f]chromene-2-carbonitrile, C21H15BrN2O2
  16. Crystal structure of 2-amino-4-(4-isopropyl-phenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2-c]chromene, C22H18N2O3
  17. Crystal structure of 3-amino-8-methoxy-1-(4-methoxy phenyl)-1H-benzo[f]chromene-2-carbonitrile, C22H18N2O3
  18. Crystal structure of monoaqua-[6,6′-((1E,1′E)-(1,2-phenylene bis(azanylylidene))bis(methanylylidene))bis(4-bromo-2-nitrophenolato-κ4N,N′,O,O′)]zinc(II), C20H12Br2N4O7Zn
  19. Crystal structure of 11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one – acetonitril (1/2), C33H41N3O2
  20. Crystal structure of tert-butyl (phenylsulfinyl)carbamate, C11H15NO3S
  21. Crystal structure of catena-poly{diaqua-bis(3-(1H-1,2,4-triazol-1-yl)benzoato-κ2O:N)copper(II)} monohydrate, C18H18CuN6O7
  22. Crystal structure of tetraaqua-bis(3-(4H-1,2,4-triazol-4-yl)benzoato-κN)cobalt(II), C18H20CoN6O8
  23. The crystal structure of 4-bromo-N-cyclopropyl-2,5-difluorobenzenesulfonamide, C9H8BrF2NO2S
  24. Crystal structure of ([3,3′-bipyridine]-6,6′-dicarboxylato-κ2O:O′)-bis(1,2-bis(4-pyridyl)ethane-κ2N:N′)disilver(I) dihydrate, C37H35Ag2N5O6
  25. The crystal structure of (4-(1H-1,2,4-triazol-1-yl)benzoato-κN)-[4-(1H-1,2,4-triazol-1-yl)benzoic acid-κN]silver(I), C18H13AgN6O4
  26. Crystal structure of 3-(4-methoxyphenyl)-1-(4-methylphenyl)prop-2-en-1-one, C17H16O2
  27. Crystal structure of bis(2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)-5-methoxyphenolato-κ2O,N)copper(II), C36H38CuN4O6
  28. Crystal structure of poly[1,2-bis(1,2,4-triazol-4-yl)ethane-κ2N:N′]silver(I) bromate monohydrate]silver(I), C6H10AgBrN6O4
  29. The crystal structure of 2,3,5-triphenyl-2,3-dihydro-1H-tetrazol-1-ium 2,3-dioxoindoline-5-sulfonate, C27H19N5O5S
  30. Crystal structure of 3-(2-amino-1,3-selenazol-4-yl)-2H-chromen-2-one – dimethylformamide (1/1), C15H15N3O3Se
  31. Crystal structure of diethyl 3,3′-(diazene-1,2-diyl)(E)-dibenzoate, C18H18N2O4
  32. Crystal structure of cis-bis((1H-benzimidazol-2-yl)methanol-κN,O)-bis(isothiocyanato-κN)nickel(II), C18H16N6NiO2S2
  33. Crystal structure of bis(2-(2′-hydroxy-5′-methoxyphenyl)-1H-benzimidazole)boron – tetrahydrofuran (1/1), C36H37N4O6B
  34. Crystal structure of poly[aqua-bis(nitrato-κ2O,O′)-(μ3-1,3-benzimidazol-3-ium-1,3-diacetato-κ4O,O′:O′′:O′′′)dysprosium(III)], C11H11DyN4O11
  35. Crystal structure of n-butyl-tris(dicyclo-hexylamido)hafnium(IV), C40H75HfN3
  36. Crystal structure of (E)-1-[1-(3-chloro-4-fluoro-phenyl)ethylidene]-2-(2,4-dinitrophenyl)hydrazine, C28H20Cl2F2N8O8
  37. The crystal structure of ethyl 4-((2-hydroxybenzyl)amino)benzoate, a Schiff base, C16H17NO3
  38. Crystal structure of 3-(2-(4-isobutylphenyl)propanoyl)-1-methylimidazolidine-2,4-dione, C17H22N2O3
  39. Crystal structure of poly[(μ3-2-(pyrazin-2-ylthio)acetato-κ3N:O:S)silver(I)], C6H5AgN2O2S
  40. Crystal structure of (E)-1-(3-((E)-((2-hydroxynaphthalen-1-yl)methylene)amino)phenyl)ethanone O-benzyl oxime, C26H22N2O2
  41. Crystal structure of (E)-2,3-dihydroxybenzaldehyde O-(2-((((E)-1-(2,5-dihydroxyphenyl)ethylidene)amino)oxy)ethyl) oxime monohydrate, C17H20N2O7
  42. Crystal structure of 4-(chloromethyl)-3-nitrobenzoic acid, C8H6ClNO4
  43. Crystal stucture of 4-((10H-phenothiazin-10-yl)methyl)-2,6-di-tert-butylphenol, C27H31NOS
  44. The crystal structure of ethyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, C13H10F3N3O4
  45. Crystal structure of catena-poly[di-(μ3-oxido-κ3O:O:O)-tetraoxido-(μ2-5′-(pyrazin-2-yl)-1H,2′H-3,3′-bi(1,2,4-triazole)-κ2N:N′)dimolybdenum(VI)], C8H6Mo2N8O6
  46. Crystal structure of (3,6-dioxocyclohexa-1,4-diene-1,4-bis(olato)-κ4O,O′:O′′,O′′′)-bis(tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′))-dizinc(II) bis(hexafluorophosphate(V)), C42H38F12N8O4P2Zn2
  47. Crystal structure of catena-poly[hexakis(μ2-2-acetylphenolato-κ3O:O,O′)trimanganese(II)], C48H42Mn3O12
  48. The crystal structure of 2,2-difluoro-4-(trifluoromethyl)-2,5-dihydro-[1,3,2]dioxaborinino[5,4-c]chromen-3-ium-2-uide, C11H6BF5O3
  49. Crystal structure of methyl (E)-2-(4-(diethylamino)-2-hydroxybenzylidene)hydrazine-1-carboxylate, C13H19N3O3
  50. The crystal structure of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, C10H15N3O2
  51. Crystal structure of 1,1-bis(η5-adamantylcyclopentadienyl)-3-phenyl-2-trimethylsilyl-2,3-dihydroisotitanazole, C42H55NSiTi
  52. Crystal structure of 2-(4-(2-(4-benzylpiperazin-1-yl)ethyl)benzyl)isoindoline-1,3-dione, C28H29N3O2
  53. Important impurity of Flupirtine – a single crystal study on ethyl (6-amino-5-((ethoxycarbonyl)amino)pyridin-2-yl)(4-fluorobenzyl)carbamate, C18H21FN4O4
  54. Crystal structure of ethyl 3-(4-methoxyphenyl)-1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-pyrazole-5-carboxylate, C22H22N2O5
  55. Crystal structure of 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate methanol solvate, C37H35N1O10
  56. The crystal structure of the inner salt of 2-[(aminoiminomethyl)amino]ethylcarbamic acid [systematic name: (2-((diaminomethylene)ammonio)ethyl)carbamate], C4H10N4O2
  57. Crystal structure of (8-hydroxy-5-nitroquinolinium) perchlorate – 8-hydroxy-5-nitroquinoline (1/1), C18H13ClN4O10
  58. The crystal structure of (5-methyl-1,2,4-oxadiazol-3-yl)ferrocene, C13H12FeN2O
  59. Crystal structure of methyl 1-(2-(fluorosulfonyl)ethyl)-2-oxocyclopentanecarboxylate, C9H13FO5S
  60. Crystal structure of the triclinic modification of 1-methyl-4-nitroimidzole, C4H5N3O2
  61. Corrigendum
  62. Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O
https://doi.org/10.1515/ncrs-2016-0384
Creative Commons
BY-NC-ND 3.0

Articles in the same Issue

  1. Cover and Frontmatter
  2. Crystal structure of poly[diaqua-(μ2-4,4′-bipyridine-κ2N:N′)manganese(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2) C42H40Cl2MnN6O10S2
  3. The crystal structure of 1,2-bis[2-methyl-5-(3-cyanophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluoro-cyclopent-1-ene, C29H16F6N2S2
  4. Crystal structure of the first characterized polymeric copper and sodium complex diaqua-(tris-acetato-κO,O′)(μ2-acetato-κO′′)dinatrium copper(II) monohydrate, C8H18CuNa2O11
  5. The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-3-yl-methylene)aniline, C18H22N2
  6. Crystal structure of methyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22N2O5
  7. Crystal structure of bis(1,3-bis(diphenylphosphino)propane-κ2P,P′)silver(I) trifluorosulfonate–methanol (1:0.5), [Ag(C27H26P2)]SO3CF3⋅0.5CH3OH
  8. Crystal structure of μ-1,4-bis(diphenylphosphine)butane-2,9-dimethyl-1,10-phenanthroline-κ2N:N′-bis(cyano-κC)dicopper(I)]-water, C58H56Cu2N6O2P2
  9. Crystal structure of N2,N6-bis(1-hydrazinyl-2-methyl-1-oxopropan-2-yl) pyridine-2,6-dicarboxamide, C15H23N7O4
  10. Crystal structure of 1,3-dimethyl-2-phenyl-1H-perimidin-3-ium iodide, C19H17IN2
  11. Crystal structure of diaqua-(2,2′-(butane-1,4-diyl)-bis(5-carboxy-1H-imidazole-4-carboxylato)-κ4O,O′,N,N′)cadmium(II) monohydrate, C14H18O11N4Cd
  12. Crystal structure of ethyl (E)-3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate, C15H14Cl2FNO3
  13. Crystal structure of bis-(1-(4-chlorophenyl)-3-phenyl-4-thenoyl-1H-pyrazol-5-ol-κ2O,O′)-(N,N-dimethylformamide)zinc(II), C43H31Cl2N5O5S2Zn
  14. Crystal structure of tetrakis(μ3-2-(N-(2-hydroxyethyl)amino)ethoxo)-tetrachloro-tetra-cobalt(II) methanol solvate, C17H44Cl4Co4N4O9
  15. Crystal structure of 3-amino-1-(4-bromophenyl)-9-methoxy-1H-benzo[f]chromene-2-carbonitrile, C21H15BrN2O2
  16. Crystal structure of 2-amino-4-(4-isopropyl-phenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2-c]chromene, C22H18N2O3
  17. Crystal structure of 3-amino-8-methoxy-1-(4-methoxy phenyl)-1H-benzo[f]chromene-2-carbonitrile, C22H18N2O3
  18. Crystal structure of monoaqua-[6,6′-((1E,1′E)-(1,2-phenylene bis(azanylylidene))bis(methanylylidene))bis(4-bromo-2-nitrophenolato-κ4N,N′,O,O′)]zinc(II), C20H12Br2N4O7Zn
  19. Crystal structure of 11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one – acetonitril (1/2), C33H41N3O2
  20. Crystal structure of tert-butyl (phenylsulfinyl)carbamate, C11H15NO3S
  21. Crystal structure of catena-poly{diaqua-bis(3-(1H-1,2,4-triazol-1-yl)benzoato-κ2O:N)copper(II)} monohydrate, C18H18CuN6O7
  22. Crystal structure of tetraaqua-bis(3-(4H-1,2,4-triazol-4-yl)benzoato-κN)cobalt(II), C18H20CoN6O8
  23. The crystal structure of 4-bromo-N-cyclopropyl-2,5-difluorobenzenesulfonamide, C9H8BrF2NO2S
  24. Crystal structure of ([3,3′-bipyridine]-6,6′-dicarboxylato-κ2O:O′)-bis(1,2-bis(4-pyridyl)ethane-κ2N:N′)disilver(I) dihydrate, C37H35Ag2N5O6
  25. The crystal structure of (4-(1H-1,2,4-triazol-1-yl)benzoato-κN)-[4-(1H-1,2,4-triazol-1-yl)benzoic acid-κN]silver(I), C18H13AgN6O4
  26. Crystal structure of 3-(4-methoxyphenyl)-1-(4-methylphenyl)prop-2-en-1-one, C17H16O2
  27. Crystal structure of bis(2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)-5-methoxyphenolato-κ2O,N)copper(II), C36H38CuN4O6
  28. Crystal structure of poly[1,2-bis(1,2,4-triazol-4-yl)ethane-κ2N:N′]silver(I) bromate monohydrate]silver(I), C6H10AgBrN6O4
  29. The crystal structure of 2,3,5-triphenyl-2,3-dihydro-1H-tetrazol-1-ium 2,3-dioxoindoline-5-sulfonate, C27H19N5O5S
  30. Crystal structure of 3-(2-amino-1,3-selenazol-4-yl)-2H-chromen-2-one – dimethylformamide (1/1), C15H15N3O3Se
  31. Crystal structure of diethyl 3,3′-(diazene-1,2-diyl)(E)-dibenzoate, C18H18N2O4
  32. Crystal structure of cis-bis((1H-benzimidazol-2-yl)methanol-κN,O)-bis(isothiocyanato-κN)nickel(II), C18H16N6NiO2S2
  33. Crystal structure of bis(2-(2′-hydroxy-5′-methoxyphenyl)-1H-benzimidazole)boron – tetrahydrofuran (1/1), C36H37N4O6B
  34. Crystal structure of poly[aqua-bis(nitrato-κ2O,O′)-(μ3-1,3-benzimidazol-3-ium-1,3-diacetato-κ4O,O′:O′′:O′′′)dysprosium(III)], C11H11DyN4O11
  35. Crystal structure of n-butyl-tris(dicyclo-hexylamido)hafnium(IV), C40H75HfN3
  36. Crystal structure of (E)-1-[1-(3-chloro-4-fluoro-phenyl)ethylidene]-2-(2,4-dinitrophenyl)hydrazine, C28H20Cl2F2N8O8
  37. The crystal structure of ethyl 4-((2-hydroxybenzyl)amino)benzoate, a Schiff base, C16H17NO3
  38. Crystal structure of 3-(2-(4-isobutylphenyl)propanoyl)-1-methylimidazolidine-2,4-dione, C17H22N2O3
  39. Crystal structure of poly[(μ3-2-(pyrazin-2-ylthio)acetato-κ3N:O:S)silver(I)], C6H5AgN2O2S
  40. Crystal structure of (E)-1-(3-((E)-((2-hydroxynaphthalen-1-yl)methylene)amino)phenyl)ethanone O-benzyl oxime, C26H22N2O2
  41. Crystal structure of (E)-2,3-dihydroxybenzaldehyde O-(2-((((E)-1-(2,5-dihydroxyphenyl)ethylidene)amino)oxy)ethyl) oxime monohydrate, C17H20N2O7
  42. Crystal structure of 4-(chloromethyl)-3-nitrobenzoic acid, C8H6ClNO4
  43. Crystal stucture of 4-((10H-phenothiazin-10-yl)methyl)-2,6-di-tert-butylphenol, C27H31NOS
  44. The crystal structure of ethyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, C13H10F3N3O4
  45. Crystal structure of catena-poly[di-(μ3-oxido-κ3O:O:O)-tetraoxido-(μ2-5′-(pyrazin-2-yl)-1H,2′H-3,3′-bi(1,2,4-triazole)-κ2N:N′)dimolybdenum(VI)], C8H6Mo2N8O6
  46. Crystal structure of (3,6-dioxocyclohexa-1,4-diene-1,4-bis(olato)-κ4O,O′:O′′,O′′′)-bis(tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′))-dizinc(II) bis(hexafluorophosphate(V)), C42H38F12N8O4P2Zn2
  47. Crystal structure of catena-poly[hexakis(μ2-2-acetylphenolato-κ3O:O,O′)trimanganese(II)], C48H42Mn3O12
  48. The crystal structure of 2,2-difluoro-4-(trifluoromethyl)-2,5-dihydro-[1,3,2]dioxaborinino[5,4-c]chromen-3-ium-2-uide, C11H6BF5O3
  49. Crystal structure of methyl (E)-2-(4-(diethylamino)-2-hydroxybenzylidene)hydrazine-1-carboxylate, C13H19N3O3
  50. The crystal structure of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, C10H15N3O2
  51. Crystal structure of 1,1-bis(η5-adamantylcyclopentadienyl)-3-phenyl-2-trimethylsilyl-2,3-dihydroisotitanazole, C42H55NSiTi
  52. Crystal structure of 2-(4-(2-(4-benzylpiperazin-1-yl)ethyl)benzyl)isoindoline-1,3-dione, C28H29N3O2
  53. Important impurity of Flupirtine – a single crystal study on ethyl (6-amino-5-((ethoxycarbonyl)amino)pyridin-2-yl)(4-fluorobenzyl)carbamate, C18H21FN4O4
  54. Crystal structure of ethyl 3-(4-methoxyphenyl)-1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-pyrazole-5-carboxylate, C22H22N2O5
  55. Crystal structure of 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate methanol solvate, C37H35N1O10
  56. The crystal structure of the inner salt of 2-[(aminoiminomethyl)amino]ethylcarbamic acid [systematic name: (2-((diaminomethylene)ammonio)ethyl)carbamate], C4H10N4O2
  57. Crystal structure of (8-hydroxy-5-nitroquinolinium) perchlorate – 8-hydroxy-5-nitroquinoline (1/1), C18H13ClN4O10
  58. The crystal structure of (5-methyl-1,2,4-oxadiazol-3-yl)ferrocene, C13H12FeN2O
  59. Crystal structure of methyl 1-(2-(fluorosulfonyl)ethyl)-2-oxocyclopentanecarboxylate, C9H13FO5S
  60. Crystal structure of the triclinic modification of 1-methyl-4-nitroimidzole, C4H5N3O2
  61. Corrigendum
  62. Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 1.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0384/html
Scroll to top button